Member Info for Notposting

I don’t need to post a fair value as the market already does that, as does the valuation at which the company can actually raise funds. And let’s not ignore the fact that those so-called “saviours” who supposedly invested “at a premium” because they only care about the science still needed warrants thrown in to get the deal done.

What exactly does O&G have to do with a pharma company? Your comparison makes no sense. I’ve also not said it’s overvalued at any point, either way, but it’s a smart attempt to deflect from being called out.

As for your suggestion that I’m “obsessed” with you. I don’t know you but suspects if I did, I still wouldn’t be. Please don’t flatter yourself as you continue to do in all your posts of self importance. You’re a random, untrustworthy, paranoid poster on a forum whose emotional outbursts are clear. You’re not significant enough for anyone to be obsessed with. Don’t mistake being called out for being relevant. It just means your nonsense needed correcting, again.

You continue making ridiculous posts to distract from your false claims. All you’re doing is ratifying the points previously made about you.

Tenantry - AI can do wonders 😉

Just to be clear. That’s not aimed at your MrJinx. I appreciate why you shared it. Thanks

The Orbital comparison is way off. Orbital was bought for 1.5 billion dollars because it has an in vivo RNA immune reprogramming *platform* and heavy backing from major venture funds and pharma partnerships. It went into that deal with serious institutional support, a big financing history and a clear strategic fit for Bristol Myers. These are completely different types of companies, with completely different technology, business models and levels of backing, so using Orbital as some sort of benchmark for Hemo’s value makes no sense at all, especially when our funding is solely from dysfunctional, self interested and deluded PIs and desperation than anything substantive, at the moment at least.

You keep posting these ridiculous comparisons and presenting them as facts, which only misleads people. The current market cap is simply what the market values Hemo at today based on risk, trial stage, funding position and execution so far. It is not a reflection of future value and it does not mean the company cannot grow from here or a major wouldn’t make an offer.

I do not disagree that Hemogenyx could one day be worth billions if it proves its science, secures the right partnerships and delivers commercially, but there is no comparison to Orbital. Totally different platforms, different investment backing, different strategic value and completely different deal dynamics.

If you want to talk fair value for Hemo, at least use proper reasoning instead of throwing out random takeover headlines and pretending they apply here.

You continue to demonstrate exactly why no one here should 1) take you seriously 2) trust you at all.

I agree. Thankfully, there are a few decent and informed posters here who keep things balanced and engage with respect. Others, though, are doing a great job of exposing themselves as bad characters, not smart voices. Their accusations, paranoia, and insults don’t impress anyone outside their little echo chamber. They’re not winning arguments; they’re just showing everyone exactly who they are.

I’m perfectly fine, emotionally steady, and able to post with a clear head. My mental health is solid, and I’m neither paranoid nor insecure. It’s just ironic seeing people call themselves serious investors or long-term holders while relying on a WhatsApp echo chamber for reassurance. That’s not conviction, that’s insecurity. Dismissing or insulting anyone with a different view doesn’t make their point stronger. If anything, it suggests they’re in over their heads, not me.

So you’re now openly claiming to have ‘inside information’ on a public forum? Bold move. I get that it’s just another attempt to mislead, but not exactly the smartest look. And as for the one referring to ‘our special friend’ and who claims to know my position, that’s straight out of the Mystic Meg club. Comedy gold, if nothing else.

Ah yes, the old ‘I can lift my phone and speak to 50% of the shareholders’ routine. Nothing screams humble investor like pretending to run the company from your bedroom.

LTHers preaching virtue while quietly offloading stock are doing a finer job of fleecing genuine holders than any so-called trader. And let’s not kid ourselves about that ‘premium’ raise. Getting a free warrant with zero risk isn’t some heroic act. It’s self-interest dressed up as strategy. Those there to “support the company” or “the science” would have contributed without fleecing fellow shareholders with warrants and further dilution. They didn’t, as the motive is, and always will be purely financial. It’s human nature.

What people tell you and what they actually do are two very different things. The market doesn’t care about your phone calls, your name-dropping or your sense of importance. It doesn’t answer to ego, it answers to progress and developments. So you can probably skip the essays highlighting “self-importance.”

Ironically, the three shouting the loudest about being ‘LTHs’ all happen to have premium accounts, Level 2 data, and spend every day glued to the board. Ask yourself why. That’s not what confident long-term investors do. That’s what people who are watching every tick because they’ve got skin in the game and an agenda to boot.

My advice. Be more wary of those who present themselves as ‘good’ than those who are openly bad. The bad can’t hurt you if you think for yourself. It’s the ones who play the good guy that can quietly twist your judgement to serve their own agenda.

No, Cyrox because it is likely they have already sold, part or all of their holding as they then have a free ride on the warrants with no risk. They’ve got nothing to lose, so of course they’ll hype it up to make as much as they can. People acting all holy usually aren’t. Trust no one.

As I can’t be bothered…

“Standard tests can tell you the patient looks clear; advanced tests tell you if the disease is truly gone.

Relying only on standard tests risks overestimating success and underestimating relapse potential.”

“CAR-T therapies often induce deep but temporary remissions. Advanced MRD testing helps confirm if the therapy achieved a true molecular remission and the kind correlated with durable outcomes.”

“Standard tests can easily miss low-level disease (below 10⁻⁴). Many AML relapses come from residual cells that were invisible to those tests.”

“So a “negative by standard tests” result might still mean the cancer is quiet, not gone.”

“Without it, it’s impossible to tell if the remission will last or relapse will occur in months.”

“Investors, regulators, and academic reviewers look for molecular-level evidence that a therapy is actually eradicating disease. Reporting only standard-test results may make the data appear encouraging but shallow and suitable for Phase I safety, not proof of efficacy.”

Absolutely false statement. If that were true, we could stop all clinical trials altogether. There is no evidence that HG-CT-1 “works,” nor has it been proven. That’s precisely what the clinical trials are designed to determine.

Judging by the number of likes on some of these posts, that’s debatable, Chris.

And whether my posts are worth reading or not… likewise.

I didn’t say the company isn’t doing well, but there’s a difference between doing well and it being a given.

Some on here talk like they’re sat in the MD Anderson boardroom! Easy on the “facts”. Speculation’s fine, just don’t dress it up as inside info constantly.

It’s amazing how much supposed “fact” turns out to be fiction. A few are getting a bit too big for their boots, and AI seems to be fuelling the overconfidence.

I’m not concerned about “stopping” a tide.

I’d be very surprised to see any significant movement just based on this after the initial hype subsides, whether that be today or over a few days, let alone a 100% increase.

But your comments just continue to be ridiculous pumps COY.

Paediatric oncology trials typically face more regulatory scrutiny, higher operational complexity, and higher per-patient costs than adult cohorts and also stricter trial stopping rules.

That said it also can broaden the commercial and strategic upside if HG-CT-1 proves safe and effective as things progress but this is a long and risky process so there should be caution.

It would be interesting if they can get a Priority Review Voucher, which I believe can also be sold on so holds its own value but again that’s if it proves successful in paediatrics I believe so the next year or so will be useful data and hopefully successful.

Until LetItRoll has sold his trade, that is.

It’s unlikely to move mountains as was expected and priced in, but still good to see progress continue.

I suspect it’s the usual pattern with a bit of hype as the so called LTHs sell into strength, then back to these levels again.

I think it would do you good to reflect on your own behaviour and perhaps take a step back. You seem to be getting unnecessarily worked up and are constantly attacking others. The use of capitals also comes across as aggressive.

You have no idea what my position is, nor do you need to.

Enjoy your weekend. I’ll certainly be enjoying mine.

On a side note, there is no such term as a “MAXIMUM shareholder”.

I only started a new thread because the post button wasn’t doing anything. I’ve never emailed LSE, and I certainly wouldn’t waste my time reporting posts. There’s also no reason for me to want posts removed that highlight such poor behaviours. If you honestly believe otherwise, it says more about your own mindset than anything else as do most of your emotionally charged posts filled with paranoia.

Do try and have a good weekend. Lay off whatever it is that’s causing such a reaction.